Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study.

Aly, Abdalla; Singh, Prianka; Korytowsky, Beata; Ling, You-Li; Kale, Hrishikesh P; Dastani, Homa B; Botteman, Marc F; Norden, Andrew D

Aly, Abdalla; Singh, Prianka; Korytowsky, Beata; Ling, You-Li; Kale, Hrishikesh P; Dastani, Homa B; Botteman, Marc F; Norden, Andrew D.

Affiliation

Aly A; Pharmerit International, Bethesda, Maryland.
Singh P; Bristol-Myers Squibb, Lawrence Township, New Jersey.
Korytowsky B; Bristol-Myers Squibb, Lawrence Township, New Jersey.
Ling YL; Pharmerit International, Bethesda, Maryland.
Kale HP; Pharmerit International, Bethesda, Maryland.
Dastani HB; Bristol-Myers Squibb, Lawrence Township, New Jersey.
Botteman MF; Pharmerit International, Bethesda, Maryland.
Norden AD; Dana-Farber Cancer Institute, Boston, Massachusetts.

Neurooncol Pract ; 7(2): 164-175, 2020 Mar.

Article in En | MEDLINE | ID: mdl-32626585

Key words

costs; glioblastoma; line of therapy; resource use; survival

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies / Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Neurooncol Pract Year: 2020 Document type: Article Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google